|
Patent landscape, scope, and claims: |
United States Drug Patent 11,648,347: Scope, Claims, and Landscape Analysis
Patent US 11,648,347, granted on May 9, 2023, to Aptalis Pharma Ireland Limited, protects a pharmaceutical composition comprising a therapeutically effective amount of budesonide. The patent focuses on a delayed-release formulation designed for treating inflammatory bowel diseases, specifically Crohn's disease and ulcerative colitis. The asserted novelty lies in a specific coating composition and a multiparticulat e dosage form, which aim to deliver budesonide to the ileum and colon.
What is the Core Innovation of Patent US 11,648,347?
The patent's core innovation is a multiparticulat e delayed-release formulation of budesonide. This formulation is engineered to release the active pharmaceutical ingredient (API) in a specific region of the gastrointestinal tract, namely the ileum and colon, to maximize local therapeutic effect while minimizing systemic exposure and associated side effects.
The formulation comprises:
- Core Pellets: Each pellet contains budesonide.
- Enteric Coating Layer: This layer is designed to prevent the premature release of budesonide in the acidic environment of the stomach.
- Delayed-Release Coating Layer: This outer layer further controls the release of budesonide, ensuring its delivery to the targeted intestinal segments.
The patent claims differentiate this formulation from prior art by specifying the composition of the delayed-release coating layer and its functional characteristics.
What are the Key Claims of Patent US 11,648,347?
Patent US 11,648,347 includes several claims directed at the pharmaceutical composition and its method of use. The most significant claims focus on the specific make-up of the delayed-release coating.
Claim 1 is a representative independent claim:
"A multiparticulat e pharmaceutical composition comprising:
a plurality of core pellets, each core pellet comprising budesonide; and
a coating on each of the core pellets, wherein the coating comprises an acrylic polymer selected from the group consisting of methacrylic acid copolymers, and wherein the coating comprises a plasticizer, and wherein the coating comprises a pore-forming agent, and wherein the coating is applied to a weight gain of from 15% to 50% by weight of the core pellet, and wherein the coated pellets exhibit less than 10% drug release after 2 hours in a medium simulating gastric fluid (pH 1.2) and exhibit at least 80% drug release after 2 hours in a medium simulating intestinal fluid (pH 6.8)." [1]
Key elements of Claim 1 and related dependent claims include:
- Active Ingredient: Budesonide.
- Dosage Form: Multiparticulat e composition (pellets).
- Coating Composition:
- Acrylic Polymer: Specifically methacrylic acid copolymers (e.g., Eudragit L, Eudragit S). These polymers are pH-dependent and dissolve at specific pH levels, enabling targeted release.
- Plasticizer: Essential for film formation and flexibility.
- Pore-Forming Agent: Facilitates water penetration and subsequent drug release in the intestinal environment.
- Coating Weight Gain: Specified range of 15% to 50% by weight of the core pellet. This parameter is critical for controlling the dissolution profile.
- In Vitro Release Profile:
- Less than 10% drug release after 2 hours in simulated gastric fluid (pH 1.2). This confirms gastric resistance.
- At least 80% drug release after 2 hours in simulated intestinal fluid (pH 6.8). This demonstrates rapid release in the target intestinal environment.
Dependent claims further refine these aspects, potentially specifying the type of acrylic polymer, the specific plasticizer or pore-forming agent, or additional functional coatings. For example, claims may specify the ratio of these components or the manufacturing process for achieving the desired pellet characteristics.
The claims are designed to capture formulations with a specific release profile that is essential for the intended therapeutic application in inflammatory bowel disease.
What is the Therapeutic Target and Significance of Budesonide Formulations Covered by this Patent?
Budesonide is a potent topical corticosteroid that is widely used to treat inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis. Its efficacy stems from its anti-inflammatory properties. However, conventional systemic corticosteroids often lead to significant side effects due to their widespread distribution throughout the body.
The therapeutic significance of the formulation protected by US 11,648,347 lies in its ability to:
- Targeted Delivery: Deliver budesonide directly to the inflamed areas of the ileum and colon, where it is most needed. This is achieved by the delayed-release mechanism, which ensures the drug is released only after passing through the stomach and duodenum.
- Reduced Systemic Exposure: By minimizing the amount of drug absorbed into the bloodstream, the formulation significantly reduces the risk of systemic corticosteroid side effects. These can include Cushingoid effects, adrenal suppression, osteoporosis, and immunosuppression.
- Improved Patient Compliance: A formulation with a favorable side effect profile and effective therapeutic outcome can lead to better patient adherence to treatment.
- Treatment of Specific IBD Locations: The formulation is particularly relevant for treating IBD affecting the distal ileum and colon, common sites for Crohn's disease and ulcerative colitis.
The patent's focus on a specific multiparticulat e delayed-release formulation addresses the long-standing challenge of achieving localized therapeutic effects of potent anti-inflammatories in the gastrointestinal tract while mitigating systemic toxicity.
What is the Patent Landscape for Delayed-Release Budesonide Formulations?
The patent landscape for delayed-release budesonide formulations is complex, reflecting years of research and development aimed at optimizing delivery and therapeutic outcomes for inflammatory bowel diseases. Several companies hold patents covering various aspects of budesonide formulations, including:
- Different Release Mechanisms: Patents may cover enteric coatings, osmotic release systems, or other novel drug delivery technologies.
- Specific Coating Compositions: Variations in polymers, plasticizers, pore-formers, and their ratios can lead to distinct patentable formulations.
- Multiparticulat e Systems: Patents may claim specific types of multiparticulat e carriers (e.g., pellets, granules, microparticles) and their manufacturing processes.
- Dosage Strengths and Regimens: Patents can also protect specific dosing strategies.
- Methods of Treatment: Claims may also encompass methods of treating specific IBD conditions using particular formulations.
Key players and their contributions to the landscape often include:
- Aptalis Pharma Ireland Limited (now part of AbbVie): This company is the assignee of US 11,648,347. Their work builds upon earlier budesonide formulations, such as those marketed as Entocort EC. Entocort EC utilizes a pH-dependent enteric coating to release budesonide in the terminal ileum and proximal colon. The patent US 11,648,347 likely represents an advancement or modification of such existing technologies, aiming for improved release characteristics or a broader therapeutic window.
- ProMetic Pharma: Holds patents related to budesonide formulations, often focusing on specific release profiles and therapeutic applications.
- Teva Pharmaceuticals: As a major generic manufacturer, Teva has also been involved in developing and patenting budesonide formulations, sometimes focusing on alternative delivery systems or bioequivalence.
- Other Specialty Pharmaceutical Companies: Numerous smaller and specialty pharmaceutical companies have developed and patented proprietary budesonide delivery systems.
Analysis of US 11,648,347 within the Landscape:
US 11,648,347 appears to build upon established delayed-release technologies, specifically targeting multiparticulat e systems with a defined coating composition (methacrylic acid copolymers, plasticizer, pore-forming agent) and stringent release specifications. The patent's strength lies in the precise definition of the coating and its performance metrics (gastric resistance, intestinal release rate).
Potential for Freedom-to-Operate (FTO) Concerns:
Companies developing generic or novel budesonide formulations for IBD must carefully assess US 11,648,347 for FTO. The specific combination of an acrylic polymer, plasticizer, pore-forming agent, defined weight gain, and the specified in vitro release profile represents a potentially crowded area of intellectual property. Competitors might need to design formulations that:
- Utilize different classes of polymers.
- Employ alternative pore-forming agents or plasticizers.
- Achieve different in vitro dissolution profiles that fall outside the claimed parameters.
- Employ entirely different drug delivery technologies (e.g., prodrugs, nanoformulations, other controlled-release mechanisms).
The patent term for US 11,648,347 is 20 years from the filing date, which was October 26, 2016. Therefore, the patent is expected to expire around October 26, 2036, subject to any potential patent term extensions.
What are the Implications for R&D and Investment in Budesonide Therapies?
The existence of US 11,648,347 has significant implications for research and development (R&D) and investment decisions in the budesonide therapy space, particularly for inflammatory bowel diseases.
For R&D:
- Design of Next-Generation Formulations: Developers seeking to enter or expand in the budesonide market must innovate beyond the specific claims of this patent. This may involve exploring:
- Novel polymer combinations for the enteric and delayed-release coatings.
- Alternative plasticizers or pore-forming agents with different performance characteristics.
- Advanced drug delivery platforms such as nanoparticles, liposomes, or sustained-release matrices that achieve targeted delivery through different mechanisms.
- Budesonide prodrugs that offer improved absorption or localized activation.
- Combination therapies where budesonide is co-formulated with other active agents, provided the formulation does not infringe existing patents.
- Focus on Manufacturing Process Patents: While this patent focuses on the composition, companies may also seek to patent novel manufacturing processes that enable the creation of unique budesonide formulations with improved properties or cost efficiencies.
- Clinical Differentiation: R&D efforts will need to demonstrate clear clinical advantages over existing budesonide products, such as improved efficacy, a better safety profile, or enhanced patient convenience, to justify investment beyond patent-protected formulations.
For Investment:
- Risk Assessment for Generic Development: Companies planning to develop generic versions of budesonide products must conduct thorough freedom-to-operate (FTO) analyses. US 11,648,347, along with other relevant patents, poses a significant hurdle. Generic developers must ensure their product's formulation and release characteristics do not fall within the scope of active claims.
- Strategic Partnerships and Licensing: Investment in companies with existing, unexpired patents on novel budesonide delivery systems, or those that can secure new IP, may be attractive. Licensing opportunities from patent holders could also be a viable strategy.
- Focus on Novel IBD Treatments: Investors may shift focus to therapies that address IBD through entirely different mechanisms of action, such as biologics (e.g., anti-TNF, anti-integrin antibodies) or small molecules targeting specific inflammatory pathways, as these may offer less crowded competitive landscapes and potentially higher unmet needs.
- Valuation of Companies with Strong IP Portfolios: Companies holding robust patent portfolios covering budesonide formulations, especially those with ongoing market exclusivity or strong FTO positions for future generic competition, may command higher valuations.
- Long-Term Investment Horizon: Given the patent expiration date of October 26, 2036, investments in budesonide-related R&D or manufacturing that depend on market exclusivity beyond this date need careful consideration.
Understanding the precise scope and limitations of patent US 11,648,347 is critical for any entity operating within the budesonide therapeutic area. It mandates careful formulation design and strategic intellectual property management.
Key Takeaways
- United States Patent 11,648,347, assigned to Aptalis Pharma Ireland Limited, protects a multiparticulat e delayed-release formulation of budesonide.
- The patent's core innovation lies in a specific coating composition and release profile designed for targeted delivery to the ileum and colon, aiming to treat inflammatory bowel diseases with reduced systemic side effects.
- Key claims define the use of methacrylic acid copolymers, plasticizers, and pore-forming agents in the coating, along with specific weight gain and in vitro release parameters (gastric resistance and intestinal release rate).
- The patent landscape for budesonide formulations is competitive, requiring careful freedom-to-operate analysis for any new product development in this therapeutic area.
- R&D and investment strategies must account for this patent's claims, potentially driving innovation towards alternative delivery mechanisms or requiring licensing agreements.
- The patent is set to expire around October 26, 2036.
Frequently Asked Questions
-
What specific types of methacrylic acid copolymers are likely covered by the patent's claims?
The claims generally refer to "methacrylic acid copolymers," which encompass polymers like Eudragit L series (dissolve at pH > 6) and Eudragit S series (dissolve at pH > 7), or combinations thereof, commonly used for enteric and colonic targeting. Specific polymer grades may be detailed in dependent claims or the patent's specification.
-
Can a generic budesonide product be developed if it uses a different enteric coating polymer, such as polyvinyl acetate phthalate (PVAP)?
If the alternative formulation using PVAP achieves a substantially different release profile or mechanism that falls outside the scope of the independent claims of US 11,648,347, it may not infringe. However, a detailed claim-by-claim analysis is necessary, considering the specific formulation details and the patent's scope.
-
Does the patent cover budesonide formulations in tablet or capsule form, or only multiparticulat e systems?
The claims, particularly Claim 1, explicitly define a "multiparticulat e pharmaceutical composition" comprising "a plurality of core pellets." Therefore, the patent's direct coverage is limited to such multiparticulat e dosage forms and does not directly cover monolithic tablets or capsules unless they incorporate these specific multiparticulat e structures.
-
What are the typical side effects of budesonide that this formulation aims to reduce?
This formulation aims to reduce systemic corticosteroid side effects, which can include Cushingoid features (e.g., weight gain, moon face), adrenal suppression, decreased bone mineral density (osteoporosis), impaired wound healing, increased susceptibility to infection, and mood changes.
-
Are there any other patents held by Aptalis Pharma Ireland Limited (or AbbVie) that might complement or extend the protection offered by US 11,648,347 for budesonide?
It is highly probable that Aptalis Pharma Ireland Limited, and subsequently AbbVie, holds a portfolio of patents related to budesonide, including those covering earlier formulations (e.g., Entocort EC), manufacturing processes, methods of treatment, or improved formulations. A comprehensive IP search would be required to identify all related patents.
Cited Sources
[1] Aptalis Pharma Ireland Limited. (2023, May 9). Pharmaceutical composition (US Patent No. 11,648,347). United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
